



**Pfizer Limited**

The Capital, 1802/1901,  
Plot No. C - 70, G Block, Bandra Kurla Complex,  
Bandra (East), Mumbai 400 051.  
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

February 3, 2022

The Corporate Relationship Dept.  
BSE Limited  
1<sup>st</sup> Floor, P.J. Towers  
Dalal Street, Fort  
Mumbai - 400 001  
Scrip Code: 500680

The Manager, Listing Dept.  
The National Stock Exchange of India Ltd.  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400 051  
Scrip Symbol: PFIZER

Dear Sirs,

**Sub: Unaudited financial results for the third quarter and nine months ended  
December 31, 2021**

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the unaudited financial results for the third quarter and nine months ended December 31, 2021, which were approved by the Board of Directors of the Company at its meeting held today, that commenced at 12.30 p.m. and concluded at 4.15 p.m.

Also please find enclosed the Limited Review Report by our Auditors – M/s. Walker Chandio & Co LLP, in respect of the above results.

Please take the above on record.

Thanking you,

Yours truly,

**For Pfizer Limited**

**Prajeet Nair**  
**Company Secretary**

**Encl: A/a**

**Cc: National Securities Depository Limited (NSDL)**  
**Central Depository Services (India) Limited (CDSL)**  
**KFin Technologies Private Limited**

## Independent Auditor's Review Report on Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

### To the Board of Directors of Pfizer Limited

1. We have reviewed the accompanying statement of unaudited financial results ('the Statement') of Pfizer Limited ('the Company') for the quarter ended 31 December 2021 and the year to date results for the period 1 April 2021 to 31 December 2021, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
2. This Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



# Walker Chandiook & Co LLP

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

## For Walker Chandiook & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013

**Ashish** Digitally signed  
by Ashish Gupta  
Date:  
**Gupta** 2022.02.03  
16:20:01 +05'30'



## Ashish Gupta

Partner

Membership No. 504662

UDIN: 22504662AAFBUG1190

**Place:** New Delhi

**Date:** 03 February 2022

**Pfizer Limited**

The Capital, 1802/1901,  
Plot No. C - 70, G Block, Bandra Kurla Complex,  
Bandra (East), Mumbai 400 051.  
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274



**Statement of Unaudited Financial Results for the Quarter and Nine months ended 31 December, 2021**

(₹ in crore except earning per share)

Particulars	3 months ended 31/12/2021	Preceding 3 months ended 30/09/2021	Corresponding 3 months ended in the previous year 31/12/2020	Year to date figures for nine months ended 31/12/2021	Year to date figures for nine months ended 31/12/2020	Previous year ended 31/03/2021
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Income						
(a) Revenue from operations	675.90	636.26	593.49	2,061.33	1,703.79	2,238.55
(b) Other income	18.26	15.03	14.57	45.53	43.92	81.12
<b>Total income</b>	<b>694.16</b>	<b>651.29</b>	<b>608.06</b>	<b>2,106.86</b>	<b>1,747.71</b>	<b>2,319.67</b>
2 Expenses						
(a) Cost of materials consumed	78.36	96.45	91.04	269.31	247.37	334.74
(b) Purchases of stock-in-trade	89.86	207.12	183.42	459.27	405.50	448.65
(c) Changes in inventory of finished goods, work-in-progress and stock-in-trade	84.15	(72.14)	(61.89)	29.74	(50.90)	14.35
(d) Employee benefits expense	109.73	107.27	94.12	311.36	266.23	361.06
(e) Finance costs	2.18	2.21	3.85	6.64	11.57	15.11
(f) Depreciation and amortization expense	27.16	27.23	27.23	81.39	82.10	109.41
(g) Other expenses	118.63	108.19	90.03	321.37	249.21	367.63
<b>Total expenses</b>	<b>510.07</b>	<b>476.33</b>	<b>427.80</b>	<b>1,479.08</b>	<b>1,211.08</b>	<b>1,650.95</b>
3 <b>Profit before tax (1 - 2)</b>	<b>184.09</b>	<b>174.96</b>	<b>180.26</b>	<b>627.78</b>	<b>536.63</b>	<b>668.72</b>
4 Tax expense						
(a) Current tax	54.85	52.09	37.91	177.73	144.56	183.63
(b) Deferred tax	(14.67)	(9.75)	1.11	(26.39)	(4.99)	(12.52)
(c) Prior year tax reversal	-	(10.33)	-	(10.33)	-	-
5 <b>Net profit for the period / year (3 - 4)</b>	<b>143.91</b>	<b>142.95</b>	<b>141.24</b>	<b>486.77</b>	<b>397.06</b>	<b>497.61</b>
6 Other comprehensive income						
(a) Items that will not be reclassified subsequently to profit or loss	0.20	0.20	(2.94)	0.60	(8.81)	(1.28)
(b) Income tax related to items that will not be reclassified to profit or loss	(0.05)	(0.05)	0.74	(0.15)	2.22	0.32
Other comprehensive income, net of taxes	0.15	0.15	(2.20)	0.45	(6.59)	(0.96)
7 <b>Total comprehensive income for the period / year (5 + 6)</b>	<b>144.06</b>	<b>143.10</b>	<b>139.04</b>	<b>487.22</b>	<b>390.47</b>	<b>496.65</b>
8 Paid-up equity share capital (Face value per share ₹10)	45.75	45.75	45.75	45.75	45.75	45.75
9 Other equity						2,347.29
10 Earnings per share - Basic and Diluted (of ₹10/- each) Computed on the basis of net profit for the period / year	31.46*	31.25*	30.87*	106.40*	86.79*	108.77

\*Earnings per share - Basic and Diluted (of ₹10/- each) not annualised

CIN: L24231MH1950PLC008311  
Email ID: [contactus.india@pfizer.com](mailto:contactus.india@pfizer.com)  
Website: [www.pfizerindia.com](http://www.pfizerindia.com)



**NOTES:**

1. The above results were reviewed and recommended by the Audit Committee, for approval by the Board, at its Meeting held on February 03, 2022 and were approved and taken on record at the Meeting of the Board of Directors of the Company held on that date.
2. The financial results of the Company have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time).
3. The financial results for quarter and nine months ended 31 December 2021 have been subjected to limited review by the statutory auditors of the Company. The limited review report does not contain any modifications. The limited review report will be filed with the Stock Exchanges and will also be available on the Company's website - [www.pfizerindia.com](http://www.pfizerindia.com)
4. The Company has only one segment which is 'Pharmaceuticals'. Therefore, disclosure relating to segments is not applicable and accordingly not made.

February 03, 2022

**For Pfizer Limited**



**S. Sridhar  
Managing Director**

